TALVEY™ is a prescription medicine used to treat adults with multiple myeloma who have already received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody to treat their multiple myeloma, and their cancer has come back or did not respond to prior treatment. TALVEY™ is approved based on patient response. Data are not yet available to show if TALVEY™ improves survival or symptoms. It is not known if TALVEY™ is safe and effective in children.
NOW APPROVED
Sign up now to stay informed about the latest updates on TALVEY™. Ask your doctor if TALVEY™ may be right for you.
What is TALVEY™?
TALVEY™ is a prescription medicine used to treat adults with multiple myeloma who:
have already received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody to treat their multiple myeloma, and
their cancer has come back or did not respond to prior treatment.
TALVEY™ is approved based on patient response. Data are not yet available to show if TALVEY™ improves survival or symptoms.
It is not known if TALVEY™ is safe and effective in children.
Sign up now to stay informed about the latest updates on TALVEY™. Ask your doctor if TALVEY™ may be right for you.
How will I receive TALVEY™?
TALVEY™ will be given to you by your healthcare provider as an injection under your skin (subcutaneous injection), usually in the stomach area (abdomen). TALVEY™ may also be injected into your thigh or another area of your body.
See “What is the most important information I should know about TALVEY™?” at the beginning of the Medication Guide for information about how you will receive TALVEY™.
If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.
More resources to get started
TALVEY™ Patient Brochure
TALVEY™ Patient Brochure
The TALVEY™ Patient Brochure will provide you with information you need to know about TALVEY™. It also has space for you to take notes and provides a few tips to help you on your TALVEY™ journey.
Sign up for the latest information about TALVEY™
Janssen Biotech, Inc., our affiliates, and our service providers will use the information that you provide to send you personalized communications about TALVEY™, relapsed or refractory multiple myeloma, and your optional requests. Your information will be used for research, development, and to improve our products and services. Please note that the subject line of email messages that you receive may include TALVEY™ or relapsed or refractory multiple myeloma. You may unsubscribe from these communications by following the instructions in them. Our Privacy Policy further governs the use of the information you provide.